Expression of chromogranins A, B, and C (secretogranin II) in human adrenal medulla and in benign and malignant pheochromocytomas An immunohistochemical study with region-specific antibodies

APMIS

Volumn 112, Issue 10, 2004, Pages 663-73

  Portela Gomes, Guida Maria ^a,b,e   Stridsberg, Mats ^b   Grimelius, Lars ^b   Falkmer, Ursula G ^c   Falkmer, Sture ^d  

^a UNIVERSITY OF LISBON   (Portugal)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^d TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^e NONE   (Portugal)

Author keywords

Chromogranin A; Chromogranin B; Chromogranin C; Human adrenal medulla; Immunohistochemistry; Malignancy grading; Pheochromocytoma; Region specific antibodies; Secretogranin II

Indexed keywords

CHROMOGRANIN A; CHROMOGRANIN B; EPITOPE; PROTEIN ANTIBODY; SECRETOGRANIN II;

ADRENAL MEDULLA; ADRENALECTOMY; ARTICLE; BENIGN TUMOR; CANCER CONTROL; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; PROTEIN STRUCTURE; SPINDLE CELL;

EID: 11944249875     PISSN: 09034641     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Falkmer S, Hansson G. Phaeochromocytomas and paragangliomas. In: Polak JM, editor. Diagnostic Histopathology of Neuroendocrine Tumours. Edinburgh: Churchill-Livingstone 1993:203-26.
2. Aunis D, Metz-Boutigue MH. Chromogranins: current concepts. Structural and functional aspects. Adv Exp Med Biol 2000;482:21-38.
3. Portela-Gomes GM, Stridsberg M. Selective processing of chromogranin A in the different islet cells in human pancreas. J Histochem Cytochem 2001;49:483-90.
4. Portela-Gomes GM, Stridsberg M. Region-specific antibodies to chromogranin B display various immunostaining patterns in human endocrine pancreas. J Histochem Cytochem 2002;50:1023-30.
5. Fischer-Colbrie R, Laslop A, Kirchmair R. Secretogranin II: molecular properties, regulation of biosynthesis and processing to the neuropeptide secretoneurin. Prog Neurobiol 15;46:49-70.
6. Galindo E, Rill A, Bader MF, et al. Chromostatin, a 20-amino acid peptide derived from chromogranin A, inhibits chromaffin cell secretion. Proc Natl Acad Sci USA 1991;88:1426-30.
7. Mahata SK, O'Connor DT, Mahata M, et al. Novel autocrine feedback control of catecholamine release. A discrete chromogranin A fragment is a noncompetitive nicotinic cholinergic antagonist. J Clin Invest 1997;100:1623-33.
8. Saria A, Troger J, Kirshmair R, et al. Secretoneurin releases dopamine from rat striatal slices: a biological effect of a peptide derived from secretogranin II (chromogranin C). Neuroscience 1993;54:1-1.
9. Portela-Gomes GM, Stridsberg M. Chromogranin A in the human gastrointestinal tract: an immunohistochemical study with region-specific antibodies. J Histochem Cytochem 2002;50:1487-92.
10. Laslop A, Doblinger A, Weiss U. Proteolytic processing of chromogranins. Adv Exp Med Biol 2000;482:155-66.
11. Portela-Gomes GM, Grimelius L, Johansson H, et al. Chromogranin A in human neuroendocrine tumors. An immunohistochemical study with region-specific antibodies. Am J Surg Pathol 2001;25:1261-7.
12. Stridsberg M, Husebye ES. Chromogranin A and chromogranin B are sensitive circulating markers for phaechromocytoma. Eur J Clin Endocrinol 1997;36:28-9.
13. Ischia R, Gasser RW, Fischer-Colbrie R, et al. Levels and molecular properties of secretoneurin-immunoreactivity in the serum and urine of control and neuroendocrine tumor patients. J Clin Endocrinol Metab 2000;85:355-60.
14. Rao F, Keiser HR, O'Connor DT. Malignant and benign pheochromocytoma. Chromaffin granule transmitters and the response to medical and surgical treatment. Ann NY Acad Sci 2002;971:530-2.
15. Harst E van der, Bruining HA, Bonjer HJ, et al. Proliferative index in phaeochromocytomas: does it predict the occurrence of metastases? J Pathol 2000;191:175-80.
16. Kumaki N, Kajlwara H, Kameyama K, et al. Prediction of malignant behaviour of pheochromocytomas and paragangliomas using immunohistochemical techniques. Endocr Pathol 2002;13:149-56.
17. Thompson LDR. Pheochromocytoma of the adrenal gland scaled score (PASS) to separate benign from malignant neoplasms. A clinicopathologic and immunophenotypic study of 100 cases. Am J Surg Pathol 2002;26:551-66.
18. Moreno AM, Castilla-Guerra L, Martinez-Torres MC, et al. Expression of neuropeptides and other neuroendocrine markers in human phaeochromocytomas. Neuropeptides 1999;33:159-63.
19. Parrado C, Falkmer UG, Höög A, et al. A technique for automatic/interactive assessment of the proliferating fraction of neoplastic cells in solid tumors. A methodological study on the Ki-67 immunoreactive cells in human mammary carcinomas, including a comparison with the results of conventional S-phase fraction assessments by means of DNA cytometry. Gen Diagn Pathol 1996;141:215-27.